<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03730428</url>
  </required_header>
  <id_info>
    <org_study_id>YOUNGBC-5</org_study_id>
    <nct_id>NCT03730428</nct_id>
  </id_info>
  <brief_title>Everolimus Related Pneumonitis in MBC</brief_title>
  <official_title>Drug-related Pneumonitis During mTOR Inhibitor Therapy in Patients With Metastatic Breast Cancer: A Radiographic Patternbased Approach</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the drug-related pneumonitis during mTOR inhibitor therapy in patients with&#xD;
      metastatic breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 15, 2017</start_date>
  <completion_date type="Actual">June 15, 2020</completion_date>
  <primary_completion_date type="Actual">May 15, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>radiographic pattern</measure>
    <time_frame>2 months</time_frame>
    <description>Quantitive measure of lung CT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>2 months</time_frame>
    <description>Progression free survival</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">86</enrollment>
  <condition>Everolimus</condition>
  <condition>Pneumonitis</condition>
  <arm_group>
    <arm_group_label>pneumonitis group</arm_group_label>
    <description>Patients who developed drug-related pneumonitis after treated with everolims</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-pneumonitis group</arm_group_label>
    <description>Patients who didn't develop drug-related pneumonitis after treated with everolims</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with breast cancer (according to ICD-10) with confirmed metastasis,&#xD;
        regardless of being de novo diagnosed or progressed from a non-metastatic stage&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Postmenopausal woman (or premenopausal women treated with LHRHa) diagnosed with&#xD;
             HR+ï¼ŒHER2- metastatic breast cancer&#xD;
&#xD;
          2. Treated with everolimus for at least one month in metastatic setting&#xD;
&#xD;
          3. With baseline and at least one follow-up chest CT during everolimus therapy.&#xD;
&#xD;
          4. Complete medical history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Incomplete medical history&#xD;
&#xD;
          2. Radiographic imaging unavailable&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biyun Wang, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fudan University Shanghai Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>November 2, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>August 16, 2020</last_update_submitted>
  <last_update_submitted_qc>August 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Biyun Wang, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

